Search NLS News

Finnish startup Finnadvance has secured a 1.2 million EUR seed financing round led by Finnish investor Athensmed. Several existing investors, such as deep tech VC Voima Ventures and early-stage VC Icebreaker, are participating in the funding round. In addition, the funding also includes a new investor: Takoa Invest. Finnadvance is a biotechnology start-up from Oulu, […]

Orion’s collaboration partner Bayer has announced the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for the oral androgen receptor inhibitor (ARi) darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The application is being conducted under the FDA Oncology […]

Ilya Pharma has announced that FDA have cleared an IND for its lead candidate ILP100-Topical and that the company is immediately accelerating preparations for large adaptive Phase 2 study, designed as a trial. ILP100-Topical is an immunotherapy designed to treat surgical wounds in patients with prediabetes, diabetes and obesity. These patients have weeks to months […]

Affibody, Acelyrin and Inmagene Biopharmaceuticals have announced that a 16-week, global, Phase 2 clinical trial of izokibep in 135 patients with psoriatic arthritis (PsA) met its primary endpoint of ACR50. Izokibep also achieved secondary endpoints, including PASI response, enthesitis LEEDs improvement, and quality of life improvement on a clinically validated PsA-specific quality of life instrument, […]

Immunicum has announced the publication of a scientific abstract that discloses new preclinical data on DCP-001, the company’s lead clinical candidate, in combination with 5’-azacitidine (5-AZA), a hypomethylating agent, and venetoclax (VEN), a BCL2 inhibitor, in a preclinical setting. The in vivo and in vitro data support the evaluation of DCP-001 as a potential combination […]

Ultomiris has been approved for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive, which represents 80% of people living with the disease. “Since bringing forward thefirst complement inhibitor, we’ve continued to listen to the community and focused innovation on the needs of gMG patients. We’re proud to […]

Emma Höglund will join the BCB Group as the Head of Growth on June 13, 2022. In the next few years, the company aims to grow outside of its core markets in the Nordics. To strengthen this development, Emma Höglund will join the company as the Head of Growth as a part of BCB Group’s […]

Spago Nanomedical has received notice from the United States Patent and Trademark Office (USPTO) that it intends to grant the company’s patent application including a critical component of the SpagoPix candidate drug SN132D. The patent will be granted following confirmation of Spago Nanomedical and payment of applicable fees, states the company. The granted patent is […]

Serendipity Partners (Serendipity) now owns 49% of the shares, however, Dr. Ola Gudmundsen will still hold the majority of the shares. The transaction is mainly structured as a share issue, where Serendipity provides growth capital to LINK Medical, states the company. Co-owners and long-term investors To enable further growth and provide new competencies to the […]

AI Medical Technologies announces the start of a clinical trial at 30 Swedish primary care facilities with Dermalyser, a diagnostic decision support system empowered with advanced artificial intelligence (AI). The study is a prospective, confirmatory multi-centre, non-interventional clinical investigation with the aim to evaluate the clinical safety, performance and benefit of Dermalyser in patients with […]